Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin Tablets (10 mg/20 mg) nationwide because the product was manufactured using an excipient that failed conductivity specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class II recall. The source text does not report any illnesses, injuries, or deaths related to the failed excipient specifications. The hazard is a manufacturing defect (out-of-specification excipient conductivity) without reported patient harm, making this a precautionary recall meeting the Moderate threshold.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Ezetimibe and Simvastatin Tablets, 10 mg/20 mg, distributed nationwide in the United States. The recall affects 30-count bottles (NDC 43598-744-30, lot numbers L100298 and L100304, expiration 01/2023) and 90-count bottles (NDC 43598-744-90, lot number L100235, expiration 01/2023).
The tablets are being recalled because they were manufactured using an excipient that failed to meet conductivity specifications. The product was manufactured by Dr. Reddy's Laboratories LA LLC in Shreveport, Louisiana, and distributed by Dr. Reddy's Laboratories Inc. in Princeton, New Jersey.
Patients currently taking this medication should contact their healthcare provider or pharmacist for guidance. Do not stop taking your medication without speaking to a healthcare professional first.
The recalled product
- Product
- EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
- Brand
- EZETIMIBE AND SIMVASTATIN
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- failed-excipient-specifications
- out-of-specification-conductivity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- a) L100298 and L100304
- exp 01/2023 b) L100235
- exp 01/2023
UPCs (4)
- 0343598745909
- 0343598742908
- 0343598743905
- 0343598744902
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · EZETIMIBE AND SIMVASTATIN
- ModerateEzetimibe and Simvastatin tablets recalled for impurity specification failure
FDA (Drugs) · 2025-06-18
- ModerateEzetimibe and Simvastatin Tablets Recalled for Defective Excipient and Foreign Tablets
FDA (Drugs) · 2021-11-17
- ModerateEzetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure
FDA (Drugs) · 2021-11-17
- ModerateDr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
FDA (Drugs) · 2021-11-10
- ModerateDr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure
FDA (Drugs) · 2021-11-10
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27